title: Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance.
abstract: Resveratrol has been reported to improve metabolic function in metabolically abnormal rodents and humans, but it has not been studied in nonobese people with normal glucose tolerance. We conducted a randomized, double-blind, placebo-controlled trial to evaluate the metabolic effects of 12 weeks of resveratrol supplementation (75 mg/day) in nonobese, postmenopausal women with normal glucose tolerance. Although resveratrol supplementation increased plasma resveratrol concentration, it did not change body composition, resting metabolic rate, plasma lipids, or inflammatory markers. A two-stage hyperinsulinemic-euglycemic clamp procedure, in conjunction with stable isotopically labeled tracer infusions, demonstrated that resveratrol did not increase liver, skeletal muscle, or adipose tissue insulin sensitivity. Consistent with the absence of in vivo metabolic effects, resveratrol did not affect its putative molecular targets, including AMPK, SIRT1, NAMPT, and PPARGC1A, in either skeletal muscle or adipose tissue. These findings demonstrate that resveratrol supplementation does not have beneficial metabolic effects in nonobese, postmenopausal women with normal glucose tolerance.
authors.affiliation: Center for Human Nutrition and Atkins Center of Excellence in Obesity Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
authors.forename: Jun
authors.initials: J
authors.lastname: Yoshino
authors.forename: Caterina
authors.initials: C
authors.lastname: Conte
authors.forename: Luigi
authors.initials: L
authors.lastname: Fontana
authors.forename: Bettina
authors.initials: B
authors.lastname: Mittendorfer
authors.forename: Shin-ichiro
authors.initials: S
authors.lastname: Imai
authors.forename: Kenneth B
authors.initials: KB
authors.lastname: Schechtman
authors.forename: Charles
authors.initials: C
authors.lastname: Gu
authors.forename: Iris
authors.initials: I
authors.lastname: Kunz
authors.forename: Filippo
authors.initials: F
authors.lastname: Rossi Fanelli
authors.forename: Bruce W
authors.initials: BW
authors.lastname: Patterson
authors.forename: Samuel
authors.initials: S
authors.lastname: Klein
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000975:Antioxidants / Q000494:pharmacology*; D001823:Body Composition / Q000187:drug effects; D019587:Dietary Supplements; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D015309:Glucose Clamp Technique; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D015990:Placebo Effect; D000077185:Resveratrol; D013267:Stilbenes / Q000097:blood / Q000494:pharmacology*
chemical_list: D000975:Antioxidants; D007328:Insulin; D013267:Stilbenes; D000077185:Resveratrol